Prasath N’s Post

2023 drug pipeline overview💊🧫: https://lnkd.in/ds4sxK8y (Nature Portfolio article) These graphs 📊 show the top 🔟 disease groups by pipeline size last year(2023). #oncology pipeline has almost as many drugs as the other 9 disease groups. This article also lists the notable approvals, regulatory setbacks and notable clinical trials from last year (take a look). Which disease group is still overlooked in your opinion? #drugdevelopment #clinicaltrials #drupapproval #pharma

Aernout van Haarst, PhD, and Sabina Paglialunga, PhD from Celerion, will be sharing their insights on oral drug absorption and GLP-1 receptor agonists drug interaction in this upcoming ASCPT webinar. Register now to secure your spot: https://lnkd.in/eH5bZbwg #Pharmacology #Webinar #DrugDevelopment #ASCPT

#AcademicTuesday How has diabetic foot ulcer affected your life? Diabetes Foot Ulcer (DFU), a common complication of diabetes, can have a significant impact on patients' quality of life. The paper "Network pharmacology and molecular docking studies on the mechanism of action of moist exposed burn ointment for treatment of diabetic foot ulcer" published in the "Tropical Journal of Pharmaceutical Research" delves into the biological active components and mechanism of action of MEBO (Moist Exposed Burn Ointment) in treating DFU. The research identifies the biological effects of MEBO are related to multiple proteins and multiple signaling pathways. Read on to see how MEBO can help you or your loved ones: https://lnkd.in/gVRU8inw #DiabeticFootUlcer #MEBO #WoundHealing #NetworkPharmacology

Happy to share that I have participated in the Indo-US Conference on "Iconic Milestones in Drug Discovery and Development," organized by KVSR Siddhartha College of Pharmaceutical Sciences. This includes two brain drug discoveries i.e., Post Partum Depression (Brexanolone) and Anti Epilepsy (Ganaxolone) by Dr. D. Samba Reddy. It was a great experience presenting my work and connecting with professionals in the field. #Pharmacy #DrugDiscovery

Nearly half of the attendees to our recent Xtalks webinar agreed that infrequent measurements and assessments during clinical studies has had the most significant negative impact on their company’s CNS drug development efforts. The Cumulus Neuroscience Platform was formed in collaboration with leading global pharmaceutical companies to enable the centralized collection of objective, longitudinal real-world data across multiple domains of brain function in clinical studies. Click here to learn more. #CNS #innovation #digitalbiomarkers https://lnkd.in/eZs-4Sh4

Nearly half of the attendees to our recent Xtalks webinar agreed that infrequent measurements and assessments during clinical studies has had the most significant negative impact on their company’s CNS drug development efforts. The Cumulus Neuroscience Platform was formed in collaboration with leading global pharmaceutical companies to enable the centralized collection of objective, longitudinal real-world data across multiple domains of brain function in clinical studies. Click here to learn more. #CNS #innovation #digitalbiomarkers https://lnkd.in/gmEhx3S4

At Cliantha, we excel in clinical research for new chemical entities (NCEs), providing comprehensive design, execution, and analysis of trials to advance innovative treatments. To learn more, write to us at: info@cliantha.com. #earlyphase #latephase #phase1 #phase2 #phase3 #phase4 #pharmaceuticals #drug #clinicaltrials #clinicalstudies #clinicalresearch #research #OphthalmologyResearch #Ophthalmology #OphthalmicTrials #NephrologyTrials #renal #kidney #nephrology

💊 The most anticipated drug launch for 2024 might just surprise you... Evaluate Ltd's annual preview report predicts that the drug KarXT used to treat schizophrenia will be the biggest launch of 2024. The drug is made by Boston based biotech, Karuna Therapeutics and has an estimated sales potential of $2.8 billion by 2028. Although you may not have heard of Karuna, you will certainly know of Bristol Myers Squibb who acquired the neurology biotech for $14 billion in late 2023. You can find a full evaluation of the top 10 most anticipated drug launches from Fierce Pharma below ⤵️ #DrugLaunch #PharmaNews #BristolMyersSquibb

💊 The most anticipated drug launch for 2024 might just surprise you... Evaluate Ltd's annual preview report predicts that the drug KarXT used to treat schizophrenia will be the biggest launch of 2024. The drug is made by Boston based biotech, Karuna Therapeutics and has an estimated sales potential of $2.8 billion by 2028. Although you may not have heard of Karuna, you will certainly know of Bristol Myers Squibb who acquired the neurology biotech for $14 billion in late 2023. You can find a full evaluation of the top 10 most anticipated drug launches from Fierce Pharma below ⤵️ #DrugLaunch #PharmaNews #BristolMyersSquibb

For the first time, the FDA has approved a medicine for metabolic dysfunction-associated steatohepatitis (MASH). MASH impacts more than 100 million people worldwide and is a leading indication for liver transplantation. The pharmaceutical industry has been attempting to target this disease for a decade, and biotechnology company Madrigal Pharmaceuticals may have finally developed an effective drug: Rezdiffra™. Despite Rezdiffra's recent success in testing and landmark FDA approval, Madrigal still faces many challenges: 1. The sales potential of drugs for the disorder have long been debated 2. Competition from new weight loss therapies being studied for MASH 3. Many patients with MASH will need combination therapy Full story from BioPharma Dive. 👇 https://lnkd.in/gBEQyGbT #FutuRxFiles #PharmaNews #LiverDisease #PharmaIndustry